Last reviewed · How we verify
Iloperidone and VHX-896 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Iloperidone and VHX-896 (Iloperidone and VHX-896) — Vanda Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Iloperidone and VHX-896 TARGET | Iloperidone and VHX-896 | Vanda Pharmaceuticals | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Iloperidone and VHX-896 CI watch — RSS
- Iloperidone and VHX-896 CI watch — Atom
- Iloperidone and VHX-896 CI watch — JSON
- Iloperidone and VHX-896 alone — RSS
Cite this brief
Drug Landscape (2026). Iloperidone and VHX-896 — Competitive Intelligence Brief. https://druglandscape.com/ci/iloperidone-and-vhx-896. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab